Compare DuPont de Nemours Inc (DD) vs UnitedHealth Group Inc (UNH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DuPont de Nemours Inc vs UnitedHealth Group Inc — how do they compare? DuPont de Nemours Inc trades at $134.41 (market cap $18.12B), while UnitedHealth Group Inc trades at $416.5 (market cap $389.68B). The key difference: UnitedHealth Group Inc is far larger — about 21.5× DuPont de Nemours Inc's market cap, and UnitedHealth Group Inc pays the higher dividend (2.16%). Which is the better fit depends on your goals.
| DD | UNH | |
|---|---|---|
Market Cap | $18.12B | $389.68B |
Sector | Basic Materials | Health |
52-Week High | $154.59 | $431.68 |
52-Week Low | $87.72 | $237.77 |
Enterprise Value | $20.58B | $436.36B |
Dividend Yield | 1.79% | 2.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DuPont (DD) trades at $132.66, down 1.5% with bearish technical signals despite recent earnings beats. The stock shows mixed fundamentals with strong gross margins (35.01%) but negative net income margin (-0.42%) and ROE (-0.16%). Analyst consensus remains bullish with a $227.20 price target (71% upside), though the company faces legal challenges and persistent net cash outflows. Recent developments include water technology upgrades and a 3:1 reverse stock split effective June 2026.
While analyst optimism and valuation discount to price target suggest potential upside, investors face significant risks including ongoing litigation over 'forever chemicals,' weak profitability trends, and concerning cash flow patterns. The stock's current technical weakness near support levels requires careful monitoring of Q2 2026 earnings results due July 2026.
UnitedHealth Group (UNH) trades at $425.19, up 0.13% on the day, with a bullish technical outlook supported by moving averages. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.23 exceeding the $6.58 estimate. Revenue grew to $447.57 billion in 2025, though net income margin compressed to 2.68%. Recent news highlights strategic moves to reduce pediatric prior authorizations and shareholder-friendly actions like dividends and buybacks.
Outlook remains positive given analyst consensus (82.69% buy ratings) and a $430.94 price target, but risks include regulatory scrutiny from lawsuits and margin pressure. The stock offers stability through dividend growth and operational scale, though investors should monitor legal developments and healthcare policy changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →About UnitedHealth Group Inc
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Read more on UNH →
